Nu-Med Plus (NUMD) Cash from Investing Activities (2012 - 2022)

Nu-Med Plus' (NUMD) quarterly Cash from Investing Activities came in at $3000.0 in Q1 2022, up 299900.0% quarter-over-quarter from $1.0 in Q4 2018.

Nu-Med Plus (NUMD) Cash from Investing Activities (2012 - 2022) Analysis & Trends

Nu-Med Plus has disclosed Cash from Investing Activities across 5 years of filings, most recently posting $3000.0 for Q1 2022.

Cash from Investing Activities for Q1 2022 came in at $3000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2022 was $3000.0 (changed N/A YoY), and the FY2018 annual result was -$5025.0, changed N/A from the prior year.
Cash from Investing Activities came in at $3000.0 for Q1 2022 at Nu-Med Plus, up from $1.0 in the prior quarter.
In the past five years, Cash from Investing Activities ranged from a high of $3000.0 in Q1 2022 to a low of -$5026.0 in Q2 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Investing Activities (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn	-20.32 Bn
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn	-185.00 Mn
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn	-816.00 Mn
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn	-591.00 Mn
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn	-92.80 Mn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	-475.32 Mn
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn	-298.50 Mn
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn	-2.50 Bn
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn	-217.20 Mn
10	Nu-Med Plus	-	-	-	-

Download Data